--- title: "Hong Kong Stock Movement: BIOSINO BIO-TEC rises 10.39%, active capital inflow attracts market attention" type: "News" locale: "en" url: "https://longbridge.com/en/news/271870273.md" description: "BIOSINO BIO-TEC rose 10.39%; Kelun-B fell 0.25%, with a transaction amount reaching HKD 1.025 billion; Innovent Biologics rose 0.62%, with a transaction amount reaching HKD 647 million; 3SBio rose 0.85%, with a transaction amount reaching HKD 422 million; BeiGene rose 0.50%, with a market value reaching HKD 307.5 billion" datetime: "2026-01-08T03:07:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/271870273.md) - [en](https://longbridge.com/en/news/271870273.md) - [zh-HK](https://longbridge.com/zh-HK/news/271870273.md) --- # Hong Kong Stock Movement: BIOSINO BIO-TEC rises 10.39%, active capital inflow attracts market attention **Hong Kong Stock Movement** BIOSINO BIO-TEC rose 10.39%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks Ranked High in Industry Transaction Volume** Kintor Pharmaceutical-B fell 0.25%. Based on recent key news: 1. On January 8, Kintor Pharmaceutical-B recorded a large transaction, with a transaction price 7.22% lower than the previous closing price, involving a total of HKD 863 million. This large transaction may lead to short-term fluctuations in market confidence regarding the stock. 2. On January 7, Kintor Pharmaceutical-B terminated the subscription of RMB 980 million for Bank of China Structured Deposit II. The company stated that this move would not have a significant adverse impact on its existing business, operations, or financial condition, but it may reflect an adjustment in the company's financial management strategy. 3. On January 5, Kintor Pharmaceutical-B's core product, Lianhua Qingwen combined with Pembrolizumab, received breakthrough therapy designation from the National Medical Products Administration. This development may have a positive impact on the company's future market performance. The pharmaceutical sector shows strong momentum in innovative drug development. Innovent Biologics rose 0.62%. Based on recent key news: 1. On January 5, Innovent Biologics performed strongly in the Hong Kong stock market, with a stock price increase of 6%. This is mainly due to capital inflow into the Hong Kong stock market after the mainland stock market reopened, especially with outstanding performance from pharmaceutical-related stocks. The rise in Innovent Biologics' stock price reflects market confidence in its innovative drugs and expectations for future growth. Source: Now News Channel 2. On January 6, several innovative products from Innovent Biologics were included in the latest medical insurance catalog, further enhancing market recognition of its products. The comprehensive pipeline layout and market potential of new products from Innovent Biologics are widely optimistic, driving the stock price up. Source: Market Value Observation 3. On January 6, Nomura Securities analysts expressed optimism about Innovent Biologics' GLP-1 weight loss drug sector, maintaining a "Buy" rating, and noted that the differentiated mechanism and pricing advantages of its products will support the company's future growth. Source: Nomura Securities Analyst Report. The pharmaceutical industry shows differentiated growth, with selected individual stocks. 3SBio rose 0.85%. Based on recent key news: 1. On January 6, 3SBio recorded a large transaction involving HKD 60.7075 million, indicating high market attention towards the stock, which pushed the stock price up. Source: Economic Information Agency 2. On January 8, CMB International released a weekly report on the pharmaceutical industry, pointing out that the Hong Kong pharmaceutical sector performed well, with 3SBio being a representative in the innovative drug field, attracting market attention. Source: Jinwu Financial News 3. On January 5, Guoyuan Securities maintained a "Buy" rating for 3SBio, with a target price of HKD 32.76, and analysts unanimously believe that the stock has strong growth potential. Source: Guoyuan Securities (HK) Analyst Report. The Hong Kong pharmaceutical sector shows outstanding performance, with evident capital inflow **Stocks Ranked Among the Top in Market Capitalization in the Industry** BeiGene rose by 0.50%. Based on recent key news: 1. On January 6, BeiGene announced that its new drug Brukinsa® received conditional approval from the National Medical Products Administration for the treatment of patients with chronic lymphocytic leukemia and mantle cell lymphoma. This approval brings new market opportunities for the company, driving up its stock price. 2. On January 5, the Hang Seng Pharmaceutical ETF surged by 5.1%, with the innovative drug sector performing strongly. BeiGene, as a representative of innovative drugs, benefited from the positive market sentiment. 3. On January 8, CMB International released a weekly report on the pharmaceutical industry, pointing out that the Hong Kong stock pharmaceutical sector performed well, with BeiGene recommended as a target rich in innovative drug catalysts, further enhancing market attention on it. The pharmaceutical sector performed strongly, benefiting innovative drugs ### Related Stocks - [08247.HK](https://longbridge.com/en/quote/08247.HK.md) ## Related News & Research - [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md) - [Monopar's ALXN1840 Shows Significant Copper Reduction In Phase 2 Trial For Wilson Disease](https://longbridge.com/en/news/287035061.md) - [Hyundai to recall over 54,000 vehicles in US over fire risk, NHTSA says](https://longbridge.com/en/news/287023935.md) - [Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy | AVAI Stock News](https://longbridge.com/en/news/287067719.md) - [Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | DTCFF Stock News](https://longbridge.com/en/news/286870222.md)